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Abstract
Diabetes is one of  the chronic diseases with a high prevalence and consequently a substantial socio-economic burden in Arab 
countries. In this paper, we propose for the first time an estimation of  the indirect economic cost of  diabetes incurred by the 
loss of  productivity caused by disability and premature mortality due to diabetes in the Arab region. The 21 countries were 
divided into three income groups and the indirect cost of  diabetes was estimated in each group. The total indirect cost was 
estimated to be around USD 72 billion whereas the average per capita indirect cost was estimated to be USD 2770, varying 
from USD 423 in group 3 to USD 7959 in Group1. The huge indirect economic cost and the associated social burden stress 
the importance that health decision makers should give to sensitisation, early diagnosis and treatment of  diabetes in the Arab 
region where the prevalence of  diabetes is very high.
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Introduction 
Once associated with economic development and considered as 
diseases of  the rich, non-communicable diseases (NCDs) are now 
affecting countries worldwide, threatening particularly economic 
and human development of  low and middle-income countries. 
Diabetes is one of  these diseases having a high prevalence and 
consequently a substantial socio-economic burden in the Arab 
region (Boutayeb A, 2006). According to the International Dia-
betes Federation Report 2011, six of  the top 10 countries with 
the highest prevalence of  diabetes (in adults aged 20 to 79 years) 
are in the Middle East: Kuwait (21.1%), Lebanon (20.2%), Qatar 
(20.2%), Saudi Arabia (20.0), Bahrain (19.9%) and UAE (19.2%) 
(IDF2011, Boutayeb et al 2012).
  
As indicated in a previous paper, diabetes raises the equity prob-
lem between and within countries (Boutayeb A and Boutayeb S 
2005). Due to its chronic nature with severe complications, this 
disease needs costly prolonged treatment and care. Consequently, 
its economical burden affects individuals, households and the 
whole society. The American Diabetes Association estimates 
that the yearly cost for treating a person with diabetes is over 
5 times more than for a person without diabetes (US$13,243 vs 
$2560). In 2007, an amount of  USD174 billion was spent on dia-
betes (USD116 billion for medical expenditures (direct costs) and 
USD58 billion (indirect costs) in reduced national productivity. It 
is estimated that the value will be more than $350 billion by 2025 
and $2.6 trillion in the next 30 years (ADA2008).
In 2003, Barcélo et al. (2003) carried out a study on the cost of  
diabetes in Latin America and the Caribbean (LAC). The 26 coun-
tries of  the LAC region were classified into four groups on the 
basis of  per capita gross national product (GNP). The loss of  
productivity due to permanent and non-permanent disability, and 
mortality related to diabetes was responsible for an indirect cost 
of  US$ 54.5 billion, representing 83.56% of  the total cost of  dia-
betes in LAC.
Following the study in LAC, Kirigia et al. (2009) proposed a simi-
lar study in the WHO African region. Evaluated in International 
dollars (PPP), the average cost per person with diabetes in groups 
1, 2 and 3 was estimated at $ 11431.6, $ 4770.6 and $ 2144.3 
respectively. The total economic loss for the whole region was $ 
25.51 billion (PPP). Indirect cost of  diabetes accounted for 43%, 
dominantly caused by permanent disability (88.5%) (Kirigia et al; 
2009).
A study carried out on the direct medical cost of  diabetes and its 
complications in the Eastern District of  Abu Dhabi emirate (Al-
Ain region) estimated that the annual direct treatment costs of  a 
diabetic patient without complications (US$ 1605) was 3.2 times 
higher than the per capita expenditure for health care in the UAE 
(US$ 497)(Al-Maskari 2010). 
In two recent papers, we estimated the direct and indirect cost 
of  diabetes in Morocco (Boutayeb et al; 2013a), and the direct 
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cost of  diabetes in the Arab region (Boutayeb et al; 2013b). The 
present paper is devoted to the estimation of  indirect cost of  
diabetes in the Arab region.
Methods
Accurate estimation of  diabetes prevalence is lacking in most 
Arab countries and reliable data on diabetes constitute a real 
problem. In absence of  registries and precise data collected in 
each Arab country, extrapolations are often used by organizations 
like the World Health Organization (WHO) and the International 
Diabetes Federation (IDF). 
In this study, following Barcélo et al (2003) and Kirigia et al 
(2009), the Arab region was divided into three income groups ac-
cording to the WHO Global Health Expenditure Atlas (WHO 
Atlas 2012) (Table 1) and the indirect cost incurred by diabetes 
was estimated in each group, using all available data in each coun-
try and extrapolating for countries where data is not available by 
assuming that the costs are similar for different countries in the 
same income group.
Prevalence of  diabetes
For the number of  people with Type2 diabetes, our study was 
based on a bibliographic research on recent studies carried out 
in different Arab countries in order to estimate the prevalence of  
diabetes mainly among adult people( 20 years and over). Our data-
base was limited to published works based on surveys respecting 
the standards of  statistical sampling techniques (population size, 
age, sex, selection criteria, etc...). In countries for which no preva-
lence was available, the value considered was the mean of  income 
group to which the country belongs.
For the number of  people with Type1 diabetes, lack and scarcity 
of  reliable data was more crucial but the previous procedure was 
followed. 
Indirect cost of  diabetes
Indirect economic cost of  a disease is mainly estimated by the 
cost of  premature mortality, permanent and temporarily disability 
caused by this illness. It should be stressed, however, that these 
non-medical costs are difficult to measure. Beside the problem 
raised by what to include in indirect costs and how to measure and 
value such economic costs, overlapping and double counting that 
may result from indirect cost estimation constitute a subject of  
discussion and debate among researchers (Bjork2001).  Usually, 
three approaches are used to estimate indirect costs of  diseases: 
human capital, willingness-to-pay and friction costs. In this study, 
following Barcélo et al (2003), we use the first approach in which 
indirect costs of  diabetes are estimated by the lifetime forgone 
earnings caused by premature death and disability due to diabetes.
•	 Mortality cost
Following the method used by Kirigia et al (2009) and using the 
probabilities of  diabetes associated deaths in different age groups 
given by Murray and Lopez (1996), the number of  productive 
years lost by people aged 15 to 60 years was estimated by sub-
tracting the averages of  age of  onset and duration of  diabetes 
from life expectancy of  the country. For children and adolescents, 
productive years lost was calculated by subtracting the averages 
of  age of  onset and duration of  diabetes plus 14 years from life 
expectancy of  the country.
•	 Cost of  permanent disability caused by dia-
betes
Following Barcélo et al (2003), we assumed that 5% of  the to-
tal population with diabetes was permanently disabled. The esti-
mated cost of  permanent disability was calculated by multiplying 
the number of  productive years lost to disability by the per capita 
GDP.
•	 Cost of  temporarily disability caused by  dia-
betes
The cost of  diabetes-related disability was estimated for people 
with diabetes aged 15 to 60 years. The cost of  disability in young 
people (0-14) and those retired (above 60 years) was ignored. It 
should be stressed that, following Barcélo et al (2003) and Kirigia 
et al (2009), we assumed that 40% of  the population with diabetes 
aged <60 years were economically active and that 60 years is the 
age of  retirement for the majority of  Arab populations.
A computer program was written, using Excel to compute all the 
economic costs.
Results and Discussion
The total indirect cost was estimated to be around USD 72 billion 
whereas the average per capita indirect cost was estimated to be 
Table1:	Arab	countries	classified	according	to	per	capita	gross	domestic	product	(GDP,	USD)
Income group
 (2010)
Per capita GNP
(USD)
Countries
1 >8000
Average: 22232
Bahrain(17379), Kuwait(46537), Lebanon(9262), Libya(12461), 
Oman(20764), Qatar(82248), Saudi Arabia(15836), UAE(39619)
2 2000-8000
Average: 3109
Algeria(4272), Egypt(2646), Iraq(2932), Jordan(4445), Moroc-
co(2848), Syria(2835), Tunisia(3831)
3 <2000
Average: 1181
Comoros(736), Djibouti(1266), Mauritania(967), Somalia(500), 
Sudan(1328), Yemen(1219)
International Journal of Diabetology & Vascular Disease Research, 2013 © 26
A. Boutayeb, W. Boutayeb, M. E. N. Lamlili, S. Boutayeb (2013) Indirect Cost of Diabetes in the Arab Region. Int J Diabetol Vasc Dis Res. 1(4), 24-28.
USD 2770, varying from USD 423 in group 3 to USD 7959 in 
Group1. The indirect cost in the first group was 7 times higher 
than in the second group and nearly 19 times higher than in the 
third group. This huge variability is explained by the use of  per 
capita income for the evaluation of  lost productivity. The average 
indirect per capita cost of  diabetes is nearly 9 times higher than 
the per capita health expenditure (Table3). The indirect cost of  
diabetes in each Arab country is given in Table Annex 1. Obvious-
ly, three parameters determine the total cost incurred indirectly 
by diabetes in each country: population size, diabetes prevalence 
and per capita GDP. Seven countries with the highest prevalence 
of  diabetes contribute to more than 75% of  the indirect cost in-
curred by diabetes in the Arab region.
For the 26 countries of  Latin America and the Caribbean, the loss 
of  productivity due to permanent and non permanent disability, 
and mortality related to diabetes was responsible for an indirect 
cost of  USD 54.5 billion, representing 83.56% of  the total cost 
of  diabetes in LAC. 
In the United States of  America, it was estimated that US$174 
billion was spent on diabetes in 2007. The indirect direct cost 
(USD 58 billion) accounted for 1/3 of  the total cost incurred by 
diabetes (ADA2007).
According to Kirigia et al (2009), the 7.02 million cases of  diabe-
tes recorded by countries of  the African Region in 2000 resulted 
in a total economic loss of  Int$ 25.51 billion with indirect cost 
accounting for Int$8.1 billion(32%) in the Region. 
Study	Limitations	and	intangible	costs
In our study, we were limited by lack and scarcity of  reliable data. 
Other limitations were related to different assumptions concern-
ing the number of  people with permanent or temporarily disabil-
ity, the proportion of  economically active population and the age 
of  retirement in each Arab country.
Diabetes is a chronic disease with a high economic burden af-
fecting rich and poor people worldwide. However, its burden 
goes beyond the limits of  economical problems. The disease in-
curs also costs that are intangible and not quantifiable such as 
inconvenience, anxiety, pain, and more generally lower quality of  
life (WHO Cost). Indeed, diabetes causes more than half  of  all 
non-traumatic lower limb amputations. It is also one of  the lead-
ing causes of  visual impairment and blindness, and the leading 
cause of  renal failure in many developing countries. How can we 
evaluate financially the loss of  vision, kidneys or lower limb? And 
how can we estimate the affective care devoted by a family to 
Table 2: Bibliographic review on prevalence of  diabetes in Arab countries
Country Author Publication date population Sample Prevalence
Algeria/Setif Malek 2001 8.2%
Algeria/Tlemcen Zaoui 2007 20 years+ 7656 14.2%
Algeria MOH STEPS 2003 25-64 4000 7.3
Bahrain Al-Mahroos 1998 40-70 2000 29.8%
Egypt	STEPS Ellabany 
et al
2005 15-65 10000 15.8%
Iraq/AlMadina Mansour 2008 20 years+ 3176 7.43%
Jordan Ajlouni 2008 25 years+ 17.1%
Jordan Ajlouni 1998 3.69%
Jordan Jordan 
STEPS
2008 18 years + 3334 16.9%
Kuwait Abdella 1998 20 years+ 3003 14.8%
Iraq MOH STEPS 2006 20 years + 1000 13.5%
Libya Kadiki 2001 20 years + 868 14.1%
Morocco Tazi 2000 20 years + 6.6%
Morocco/Oujda Ramdani 2012 40 years+ 1628 10.2%
Oman Asfour 1995 5096 10%
Oman Al-Lawati 2002 20 years + 5838 11.5%
Oman Al-Moosa 2006 20 years+ 7179 U:17.7 ; R:10.5
Qatar Bener 2009 20 years+ 1117 16.7%
Saudi	Arabia Al-Nuaim 1997 15 years + 13177 UM12 ; UF14 RM7 ; RF8
Saudi	Arabia El-Hazmi 1998 2-77 years 25337 M:5.63   F:4.53
Saudi	Arabia Al-Nozha 2004 30-70 years 16917 23.7
Saudi	Arabia	 MOH-
WHO
2005 25-64 1768 19.2%
Tunisia Bouguerra 2008 20 years+ 3729 9.9%
UAE/Al	Ain Saadi 2007 20 years+ 2455 17.1%
UAE Malik 2005 20 years+ 5844 20%
Yemen AlHabori 2004 25 years+ 498 4.6%
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one of  its members affected by diabetes complications? As in-
dicated earlier, the treatment of  diabetes appears not only as an 
economic problem but also as a sustainable development issue. 
For this reason, health decision makers should consider such a 
disease in its integrated context, requiring health education and 
sensitization, early diagnosis and efficient treatment to avoid com-
plications or at least to delay them as far as possible. For instance, 
the budget required for sensitization, diagnosis and treatment of  
diabetes without complications is cost-efficient compared to the 
socioeconomic burden imposed by blindness, kidney failure or 
foot amputation. 
Conclusion
Despite the limitations imposed by lack and scarcity of  reliable 
data concerning the number of  people with diabetes in the Arab 
countries and the large variability of  prices, our study proposes 
for the first time an estimation of  the indirect economic cost of  
diabetes incurred by the loss of  productivity caused by disability 
and premature mortality due to diabetes. The huge indirect eco-
nomic cost and the associated social burden stress the importance 
that health decision makers should give to sensitisation, early di-
agnosis and treatment of  diabetes in the Arab region where the 
prevalence of  diabetes is very high.
JEL	classifications: I11, I13, I15, J14
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